Mylan Inc. / Agila Specialties (Strides Arcolab)

Generic Sterile Injectables

Disease Overview

Generic sterile injectables span hospital-administered oncolytics, antibiotics, anesthetics, and emergency drugs. The category is structurally supply-constrained — chronic shortages, FDA quality actions, and high capital intensity for sterile fill-finish capacity create premium economics for scaled, FDA-compliant manufacturers.

Competitive Landscape

In 2013 the global injectable generics market was projected to grow ~13% CAGR through 2017, outpacing oral solids and creating a consolidation race. The category leaders heading into the deal were Hospira (the established #1 in US sterile injectables, later acquired by Pfizer in 2015), Sandoz/Novartis, Teva, Fresenius Kabi, and Hikma — each pursuing capacity build-outs as Hospira and Ben Venue grappled with FDA quality issues that drove persistent shortages. Mylan's pre-deal injectable footprint (~500 marketed products, 55 ANDAs) lagged the top tier; Agila brought 300+ approvals across 70 countries plus 350+ pending filings and nine FDA-cleared facilities in India, Brazil, and Poland, vaulting the combined platform to top-three globally and ~70% of regulated-market injectable demand. The FTC required divestiture of 11 overlapping injectables to clear the deal, confirming the competitive overlap. The deal mattered because it converted Mylan from a primarily-oral-solids generics player into a credible institutional/hospital-channel competitor heading into a wave of biosimilar and complex-injectable opportunities.